SCHEMBL13166556

SCHEMBL13166556

CC(C)N(CCNC(C)(C)C)C(C)C

nearest known ligand 0.40

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26350478 0.85 MEN1 (0.33) MEN1KMT2A
SCHEMBL3157252 0.81 MEN1 (0.37) MEN1KMT2AALDH1A1
SCHEMBL7112182 0.81 MEN1 (0.33) MEN1KMT2A
SCHEMBL19966969 0.78
SCHEMBL19286534 0.76
SCHEMBL7282809 0.73 MEN1 (0.31) MEN1KMT2AALDH1A1
SCHEMBL5932747 0.73 MEN1 (0.48) MEN1KMT2AALDH1A1
SCHEMBL17708254 0.73
SCHEMBL7367901 0.72 MEN1 (0.42) MEN1KMT2AALDH1A1
SCHEMBL24515158 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11459308-B2 Broad spectrum inhibitors of filoviruses MICROBIOTIX, INC. (US) 2022-10-04 US disclosed
CN-107250094-B For extracting C from aqueous streams1To C4Quaternary phosphinate salts of carboxylic acids and co-solvents 伊士曼化工公司 2021-07-06 CN disclosed
CN-107257784-B For extracting C from aqueous streams1To C4Quaternary carboxylate compositions of carboxylic acids 伊士曼化工公司 2021-07-06 CN disclosed
CN-107406469-B For extracting C from aqueous streams1To C4Quaternary arylcarboxylate salt compositions of carboxylic acids 伊士曼化工公司 2021-04-30 CN disclosed
US-20190292165-A1 BROAD SPECTRUM INHIBITORS OF FILOVIRUSES MICROBIOTIX, INC. (US) 2019-09-26 US disclosed
EP-3233872-A1 QUATERNARY CARBOXYLATE COMPOSITIONS FOR EXTRACTING C1 TO C4 CARBOXYLIC ACIDS FROM AQUEOUS STREAMS Eastman Chemical Company (US) 2017-10-25 EP disclosed
US-9611209-B1 Quaternary arylcarboxylate compositions for extracting C1 to C4 carboxylic acids from aqueous streams EASTMAN CHEMICAL COMPANY (US) 2017-04-04 US disclosed
US-20170008888-A1 HETEROCYCLIC COMPOUNDS ACTIVX BIOSCIENCES, INC. 2017-01-12 US disclosed
WO-2016100768-A1 QUATERNARY CARBOXYLATE COMPOSITIONS FOR EXTRACTING C1 TO C4 CARBOXYLIC ACIDS FROM AQUEOUS STREAMS EASTMAN CHEMICAL COMPANY (US) 2016-06-23 WO disclosed
US-20160175737-A1 Quaternary Carboxylate Compositions for Extracting C1 to C4 Carboxylic Acids from Aqueous Streams EASTMAN CHEMICAL COMPANY (US) 2016-06-23 US disclosed
US-8470850-B2 Inhibitors of VEGF receptor and HGF receptor signalling METHYLGENE INC. (CA) 2013-06-25 US disclosed
US-20100249145-A1 Inhibitors of VEGF Receptor and HGF Receptor Signaling METHYLGENE, INC. 2010-09-30 US disclosed
US-20100249145-A1 Inhibitors of VEGF Receptor and HGF Receptor Signaling METHYLGENE, INC. 2010-09-30 US disclosed
US-7790729-B2 Inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE INC. (CA) 2010-09-07 US disclosed
US-7790729-B2 Inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE INC. (CA) 2010-09-07 US disclosed
US-20100216766-A1 Inhibitors of VEGF Receptor and HGF Receptor Signalling 92229129 QUEBEC INC. (CA) 2010-08-26 US disclosed
US-7772247-B2 Substituted thieno[3,2-d]pyridines as inhibitors of the VEGF receptor and HGF receptor METHYLGENE INC. (CA) 2010-08-10 US disclosed
US-7772247-B2 Substituted thieno[3,2-d]pyridines as inhibitors of the VEGF receptor and HGF receptor METHYLGENE INC. (CA) 2010-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170008888-A1 HETEROCYCLIC COMPOUNDS BET1, EP300, RBBP5 MEN1 1184/4885KMT2A 1805/4885ALDH1A1 3922/4885
US-20100249145-A1 Inhibitors of VEGF Receptor and HGF Receptor Signaling HGF, MET, FLT1 MEN1 3655/4885KMT2A 3391/4885ALDH1A1 1649/4885
US-11459308-B2 Broad spectrum inhibitors of filoviruses NPC1L1, NPC1, GBA1 MEN1 3758/4885KMT2A 4257/4885ALDH1A1 3771/4885
US-20100216766-A1 Inhibitors of VEGF Receptor and HGF Receptor Signalling HGF, MET, FLT1 MEN1 3623/4885KMT2A 3438/4885ALDH1A1 1821/4885
US-20190292165-A1 BROAD SPECTRUM INHIBITORS OF FILOVIRUSES NPC1L1, NPC1, GBA1 MEN1 3758/4885KMT2A 4257/4885ALDH1A1 3771/4885
US-20160175737-A1 Quaternary Carboxylate Compositions for Extracting C1 to C4 Carboxylic Acids from Aqueous Streams SLC16A3, CA4, SLC16A1 MEN1 2014/4885KMT2A 3494/4885ALDH1A1 1180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.